<DOC>
	<DOCNO>NCT01655147</DOCNO>
	<brief_summary>The purpose study assess effect repeat daily administration rifampicin pharmacokinetics ( body medication ) abiraterone follow single-dose administration abiraterone acetate tablet healthy male participant .</brief_summary>
	<brief_title>A Study Evaluate Effect Rifampicin Pharmacokinetics Abiraterone Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center ( study conduct one site ) , 2-period , sequential-design ( study combine longitudinal cross sectional method ) , evaluate effect rifampicin pharmacokinetics abiraterone acetate healthy male participant . The study consist screen phase , open-label treatment phase , follow phase . The screening phase within 14 day first study medication administration . The treatment phase consist 2 treatment period , Period 1 : single oral dose abiraterone acetate tablet , Period 2 : daily oral dose rifampicin capsule alongwith single oral dose abiraterone acetate tablet . The 2 period separate washout period least 7 day . Blood sample collection pharmacokinetic assessment do determination abiraterone rifampicin concentration . The follow phase 14 day . Safety evaluation adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The total study duration approximately 31 day .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Must blood pressure 90 140 mmHg systolic , inclusive , high 90 mmHg diastolic Must 12lead electrocardiogram consistent normal cardiac conduction function Must sign inform consent document indicate understand purpose procedure require study willing participate study Must agree use adequate contraception method donate sperm study 3 month receive last dose study medication Have willingness participate optional pharmacogenomic component study , participant ( legally acceptable representative ) must sign informed consent form History current clinically significant medical illness include cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder , lipid abnormality , others Clinically significant abnormal value hematology clinical chemistry screen admission study center Serum testosterone level &lt; 200 ng/dL ( screen ) Clinically significant renal laboratory finding include specifically , creatinine , creatinine clearance Clinically significant hepatic laboratory finding sign</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>JNJ-589485</keyword>
	<keyword>JNJ-212082</keyword>
	<keyword>Zytiga</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Rifadin</keyword>
	<keyword>CYP3A4 inducer</keyword>
</DOC>